NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced initial results from the Company's Phase 1 study evaluating azercabtagene zapreleucel (azer-cel), an investigational, allogeneic CD19-directed chimeric antigen receptor (CAR) T-cell therapy, in patients with progressive multiple sclerosis (MS). The data represent the first reported clinical evaluation of an allogeneic CD19-directed CAR T-cell therapy in progressive MS and were presented in a late-breaking oral sess.

Single-dose miv-cel continues to demonstrate promising clinical benefit in progressive multiple sclerosis, achieving robust CAR T-cell penetration in the central nervous system (CNS) and improving disability scores while removing the need for chronic immunotherapies

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CARTCellTherapy--Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients.

Diversify Advisory Services LLC lifted its stake in The Progressive Corporation (NYSE: PGR) by 39.8% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 14,250 shares of the insurance provider's stock after acquiring an additional 4,058 shares during the period. Diversify Advisory Services LLC's

Progressive (PGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PGR's rising auto premiums, expanding policy base and improved underwriting profitability support growth as competition intensifies in the U.S. auto market.

Progressive (PGR) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The Progressive Corp. is rated a 'Hold,' reflecting strong underwriting and durable demand but tempered by slowing premium growth and uncertain earnings momentum. PGR's Q3 2026 combined ratio improved to 88.7%, yet net premiums written grew just 4% YoY, with September monthly growth slowing to 2%. Valuation appears fair at a trailing P/E of 10.7x, but a weaker forward EPS outlook could pressure the multiple and limit upside.